CDKN2A and head and neck cancer: Head and neck cancers with heightened sensitivity to Chk1i were found to have higher levels of CDKN2A/p16 deletion24, while Chk1i-responsive small cell lung carcinoma cell lines featured increased activation of oncogenic Myc4.